Table 2.

Summary of prelicensure trials on HPV vaccine efficacy in younger females.

Trial	Number of Participants	Participant Ages	Efficacy against Vaccine-Type CIN2+
Gardasil®
FUTURE I and II [33] NCT00092521 and NCT00092534	12,167	15–26	98%
Cervarix®
PATRICIA [37] NCT00122681	18,644	15–25	92.9%
CVT [39] NCT00128661	7466	15–25	89.5%
Gardasil 9®
NCT00543543 [42]	14,215	16–25	97.1%
Cecolin ®
NCT01735006 [45]	3723	18–26	100%